Jagiellonian University Medical College is the oldest medical school in Poland. The Jagiellonian University's Faculties of Medicine and Pharmacy are acclaimed as one of the largest medical academies in Poland. The school was established by King Casimir III of Poland in 1364.

During the past decade, Uniwersytet Jagielloński Collegium Medicum conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Uniwersytet Jagielloński Collegium Medicum" #1 sponsor was "Celgene" with 3 trials, followed by "Bristol-Myers Squibb" with 1 trials sponsored, "European Myeloma Network" with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored and "Occlutech International AB" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Uniwersytet Jagielloński Collegium Medicum" #1 collaborator was "Janssen Research & Development, LLC" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Uniwersytet Jagielloński Collegium Medicum" are "Multiple Myeloma" (2 trials), "Hypertrophic Cardiomyopathy" (1 trials), "Lymphoma, Mantle-Cell" (1 trials), "Mantle Cell Lymphoma" (1 trials) and "Myelodysplastic Syndrome" (1 trials). Many other conditions were trialed in "Uniwersytet Jagielloński Collegium Medicum" in a lesser frequency.

Most popular intervention types in "Uniwersytet Jagielloński Collegium Medicum" are "Drug" (6 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Daratumumab" (2 trials), "Lenalidomide" (2 trials), "Best Supportiv Care (BSC)" (1 trials), "Bortezomib" (1 trials) and "Dexamethasone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Uniwersytet Jagielloński Collegium Medicum" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Uniwersytet Jagielloński Collegium Medicum". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Uniwersytet Jagielloński Collegium Medicum, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Uniwersytet Jagielloński Collegium Medicum, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".